contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


kdventures-portfolio-company-anacardio-extends-ip-protection-for-ac01-until-the-2040s-with-new-us-patent-approval

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

KDventures is an investment company focused on long-term equity investments in biotechnology and pharmaceutical companies. The company's goal is to develop promising medical innovations stemming from academic research at Karolinska Institutet and other universities in the Nordic region. The company's portfolio includes companies in sectors such as biotechnology and medical technology. KDventures was founded in 2003 and is headquartered in Solna, Sweden.

KDventures

STOCKHOLM, SWEDEN March 11, 2026. KDventures AB (Nasdaq Stockholm: KDV) today announces that its portfolio company AnaCardio has received approval for a US patent covering the use of AC01 for...

<div class="mfn-preamble"><p><strong>STOCKHOLM, SWEDEN March 11, 2026. KDventures AB (Nasdaq Stockholm: KDV) today announces that its portfolio company AnaCardio has received approval for a US patent covering the use of AC01 for the treatment of heart failure with reduced ejection fraction (HFrEF). The issued patent extends the IP protection for AC01 in the US until the 2040s.</strong></p></div><div class="mfn-body"><p>AnaCardio AB is a privately held Swedish clinical-stage biopharmaceutical company developing novel drugs for the treatment of heart failure. In December 2025, the company’s lead asset, AC01, demonstrated a favorable safety and tolerability profile in a phase 2a clinical study.</p><p>The United States Patent and Trademark Office, USPTO, has now issued a new patent for AC01 that is co-owned by AnaCardio AB and Helsinn Healthcare SA. The new patent provides protection in the US until June 2, 2042, excluding potential patent term extensions.</p><p>”This patent bolsters protection for our portfolio company’s drug candidate AC01 on the US market and strengthens its commercial potential as well as the prospects for continued clinical development in a therapeutic area with great medical need," says Viktor Drvota, CEO of KDventures.</p><p>KDventures’ ownership in AnaCardio amounts to 10 percent.</p></div><div class="mfn-footer mfn-contacts mfn-4ff2cb3ad197"><p><strong class="mfn-heading-1">Contacts</strong><br>Viktor Drvota, CEO, KDventures AB<br>Phone: +46 73 982 52 02, e-mail: <a href="mailto:viktor.drvota@kd-ventures.com" rel="noopener">viktor.drvota@kd-ventures.com</a><a href="mailto:viktor.drvota@kd-ventures.com" rel="noopener"><br></a><br>Johan Dighed, General Counsel and Deputy CEO, KDventures AB<br>Phone: +46&nbsp;70&nbsp;207 48 26, e-mail: <a href="mailto:johan.dighed@kd-ventures.com" rel="noopener">johan.dighed@kd-ventures.com</a></p></div><div class="mfn-footer mfn-about mfn-e5c635050322"><p><strong class="mfn-heading-1">About Us</strong><br>KDventures AB (Nasdaq Stockholm: KDV) is a Nordic investment company specialized in life sciences. The company identifies and invests in innovative pharmaceutical projects and medical technology products originating from leading research institutions in the Nordic region. Through a diversified portfolio across various stages of development, professional due diligence, and active board engagement, KDventures creates value from early research to commercialization. The company offers investors exposure to both listed and private life science projects with significant value growth potential.<br>For more information, please visit <a href="https://www.globenewswire.com/Tracker?data=Ji2t-FdpXNxyFV_aNm2Es1jblYjQRjRAt5G3nUC9SEuC0msoxOtb8c51FdXkSp84Usn0qazp_-tVuKC4LQ3lzpjnT8UnA52e96qEEZAWd3F9C02CJDOvrs9iH7hw4lA3" rel="noopener">www.karolinskadevelopment.com</a>.</p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong><br><a class="mfn-generated mfn-primary" href="https://storage.mfn.se/1ebbf886-b2b6-4895-a85b-e9363b8bb86c/kdventures-portfolio-company-anacardio-extends-ip-protection-for-ac01-until-the-2040s-with-new-us-patent-approval.pdf" rel="noopener">KDventures’ portfolio company AnaCardio extends IP protection for AC01 until the 2040s with new US patent approval</a></p></div>

KDventures’ portfolio company AnaCardio extends IP protection for AC01 until the 2040s with new US patent approval